Table 3.

Linear regression for predicting changes in the fine motor/handwriting subscale of the DCDQ

	Model 1		Model 2		Model 3		Model 4		Model 5
	β	p	β	p	β	p	β	p	β	p
Age	-0.038	0.647	-0.021	0.803	-0.038	0.641	-0.037	0.649	0.003	0.968
Female*	-0.029	0.726	-0.015	0.852	-0.023	0.773	-0.023	0.778	-0.035	0.659
FSIQ	-0.150	0.072	-0.145	0.079	-0.151	0.064	-0.150	0.066	-0.151	0.061
Atomoxetine†	-0.003	0.967	0.014	0.859	0.034	0.675	0.037	0.645	-0.002	0.976
P-reported ARS-I (Δ)	-0.179	0.029	-0.171	0.035	-0.168	0.037	-0.169	0.036	-0.174	0.029
ATA-V-OME (Δ)			-0.163	0.046	-0.141	0.083	-0.153	0.072	-0.140	0.095
ATA-V-RT (Δ)					-0.172	0.034	-0.253	0.169	-0.165	0.370
ATA-V-RTV (Δ)							0.092	0.623	0.003	0.987
ATA-A-CME (Δ)									0.191	0.022
Adjusted R2	0.035		0.054		0.078		0.073		0.100

^*reference group: male;

^†reference group: methylphenidate.

ARS, attention-deficit/hyperactivity disorder rating scale; ATA, Advanced Test of Attention; A-CME, auditory commission error; DCDQ, Developmental Coordination Disorder Questionnaire; FSIQ, full scale intelligence quotient; P-reported ARS-I, parent-reported ARS-inattention; V-OME, visual omission error; V-RT, visual response time; V-RTV, visual response time variability